Smith & Nephew (LSE:SN)(NYSE:SNN), the global medical
technology business, announces the publication of a new research
paper showing how a comprehensive ulcer prevention programme which
included the use of ALLEVYN™ LIFE can significantly decrease
hospital-acquired pressure ulcers (HAPUs).1
The study was conducted in an adult intensive care unit (ICU) at
Eskenazi Health, Indianapolis, Indiana, US, between 2012 and 2013,
and published in the American Journal of Critical-Care Nurses.
The research emphasises that hospitals who adopt a standardised
protocol for the prevention and treatment of HAPUs may see
potential cost benefit of such prevention. At the end of the first
year, the prevention programme demonstrated a 69% decrease in
HAPUs.1 The estimated potential cost saving for the Eskenazi Health
ICU was nearly $1 million, and the convincing results in the ICU
have led to the approval of a hospital-wide rollout of the HAPU
prevention programme. 1
ALLEVYN™ LIFE, a silicone foam dressing also indicated for the
treatment and prevention of pressure ulcers, developed by Smith
& Nephew, was introduced to the protocol as part of the
standard prevention method three months into the programme.
Rachel Culpepper, Registered Nurse at Eskenazi Health stated,
“This study validates the need for a comprehensive, proactive,
collaborative prevention programme in hospitals. Although it is
difficult to isolate the effects of individual programme
components, silicone foam dressings can complement an existing
pressure ulcer prevention programme, and are believed to contribute
to the reduction in HAPUs.”
“Smith & Nephew has a strong heritage of innovation in
advanced wound management. By sharing the meaningful data
results, we hope to increase awareness and emphasise the
importance of prevention programmes for hospital-acquired pressure
ulcers,” said Bert Slade, MD, Chief Medical Officer, Advanced Wound
Management, Smith & Nephew. “Our mission is to support
healthcare professionals to improve lives of patients. We welcome
these findings and strongly believe they will help healthcare
providers, clinicians and administrators to better manage the
clinical and economic burden of HAPUs in similar settings
worldwide.”
Additional components to the HAPU prevention programme include
educating Eskenazi Health staff members and a focus on adherence to
protocols for patient care. Both have proven to be part of an
effective programme for reducing the incidence of HAPUs in the ICU,
according to the study results.1
- Ends -
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma &
Extremities, Smith & Nephew has around 15,000 employees and a
presence in more than 100 countries. Annual sales in 2015 were more
than $4.6 billion. Smith & Nephew is a member of the FTSE100
(LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our
website www.smith-nephew.com, follow @SmithNephewplc on Twitter or
visit SmithNephewplc on Facebook.com.
Smith & Nephew will be presenting more of the latest
research on pressure ulcer prevention at WUWHS 2016. To learn more
go to http://www.smith-nephew.com/wuwhs2016/.
About Hospital-Acquired Pressure Ulcers (HAPUs)
In acute care settings, the estimated incidence and standard of
care for HAPUs varies widely around the world.2, 3 HAPUs are
largely preventable, although they are costly to treat, and these
costs are typically not reimbursed by insurance payers.4 The
estimated average cost is USD 38,700 per incidence.1 Standard
recommendations for prevention have helped to drive down the
incidence of HAPUs, but there remains room for further
improvements.2
About the Eskenazi Health Study1
Eskenazi Health, one of the largest essential health systems in
the US, based in Indianapolis, Indiana, initiated a study in an
adult ICU with the goal of reducing the incidence of HAPUs by 50%.
The prevention programme involves:
- A risk-stratified approach to care,
based on Braden sources: high risk (≤ 12); moderate (12–14); at
risk (15–18)
- Use of a revised skincare protocol,
fluidised repositioners, staff education and awareness
improvement
- Use of ALLEVYN™ LIFE adhesive dressings
over bony prominences, including elbows, heels, knees, sacrum and
shoulders
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
◊ Trademark of Smith & Nephew. Certain marks registered US
Patent and Trademark Office.
References
1 Swafford K, Culpepper R, Dunn C. Use of a Comprehensive
Program to Reduce the Incidence of Hospital-Acquired Pressure
Ulcers in an Intensive Care Unit. Am J Crit Care. 2016
Mar;25(2):152-5
2 Mallah Z, Nassar N, Kurdahi Badr L. The effectiveness of a
pressure ulcer intervention program on the prevalence of hospital
acquired pressure ulcers: controlled before and after study. Appl
Nurs Res. 2015;28(2):106-113.
3 Santamaria N, Liu W, Gerdtz M, et al. The cost-benefit of
using soft silicone multilayered foam dressings to prevent sacral
and heel pressure ulcers in trauma and critically ill patients: a
within-trial analysis of the Border Trial. Int Wound J.
2015;12(3):344-350.
4 Department of Health and Human Services. Center for Medicare
and Medicaid Services. SMDL #08-004. July 31, 2008. State Medicaid
Director letter
https://downloads.cms.gov/cmsgov/archived-downloads/SMDL/downloads/smd073108.pdf
Accessed May 24, 2016.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160706005152/en/
MadanoKarley Ura+44 (0) 20 3595 2415orJaclyn Confalone+44 (0) 20
3595 2441
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Mar 2023 to Mar 2024